Kadikoy Medicana Hospital, Zuhtupasa Recep Peker Caddesi No:11, 34724 Mahallesi, 34724, Kadıkoy/Istanbul - Turkey.
J Invasive Cardiol. 2020 Jun;32(6):E158-E167. doi: 10.25270/jic/20.00058.
Buerger's disease, or thromboangiitis obliterans, is associated with limb-threatening chronic arterial lesions. In this study, we sought to investigate the efficacy of the percutaneous transluminal angioplasty method for the treatment of critical limb ischemia (CLI) in patients with Buerger's disease in our modest cohort.
Patients diagnosed with CLI secondary to Buerger's disease who underwent percutaneous transluminal angioplasty between May 2014 and June 2017 were retrospectively investigated. Patient demographics, presentations, procedural details, responses to percutaneous treatment, complications, limb salvage, wound healing, reinterventions, and early follow-up data were recorded.
The cohort included 24 patients with Buerger's disease presenting with CLI observed in 46 limbs. Presentations were gangrene in 12 patients, ulcer formation in 7 patients, and rest pain in the remaining 5 patients. All patients received percutaneous balloon angioplasty, with limb salvage in 21 patients (87.5%). Revascularization was achieved in 87.5% of the destination arteries at the primary intervention and overall technical success rate including reinterventions reached 95.8%. Following the procedures, a total of 22 patients had clinical response with at least ≥1 Rutherford category and mean Rutherford category significantly improved from 5.2 ± 0.74 to 1.6 ± 0.7 (P<.001). Limb salvage rate was 87.5%. Complete wound healing was achieved in all patients with ischemic ulcers at 3.9 ± 2.6 months (range 1-13 months) post revascularization. Mean follow-up duration was 16.07 ± 3.4 months and 6 patients (who were especially subjected to cigarette smoke) required reinterventions.
Percutaneous treatment of arterial occlusions in patients with Buerger's disease seems feasible in the current era of improving devices and angioplasty materials. Procedures may be safely performed with good technical and clinical success rates, and without mortality or complications as experience increases.
伯格氏病,又称血栓闭塞性脉管炎,与威胁肢体的慢性动脉病变有关。在本研究中,我们旨在探讨经皮腔内血管成形术治疗伯格氏病合并严重肢体缺血(CLI)的疗效。
回顾性分析 2014 年 5 月至 2017 年 6 月期间接受经皮腔内血管成形术治疗的 24 例伯格氏病合并 CLI 患者。记录患者的人口统计学资料、临床表现、手术细节、经皮治疗反应、并发症、保肢率、伤口愈合、再介入治疗和早期随访数据。
本队列包括 24 例伯格氏病合并 CLI 患者,46 条肢体出现症状。临床表现为 12 例坏疽、7 例溃疡形成、5 例静息痛。所有患者均接受经皮球囊血管成形术治疗,21 例(87.5%)患者保肢成功。初次介入治疗时,87.5%的靶血管再通,包括再次介入治疗的总技术成功率为 95.8%。术后,22 例(91.7%)患者临床症状改善至少 1 个 Rutherford 分级,平均 Rutherford 分级从 5.2±0.74 显著改善至 1.6±0.7(P<.001)。保肢率为 87.5%。所有缺血性溃疡患者均在血管重建后 3.9±2.6 个月(1-13 个月)完全愈合。平均随访时间为 16.07±3.4 个月,6 例患者(尤其受吸烟影响)需要再次介入治疗。
在目前不断改进的设备和血管成形术材料时代,经皮治疗伯格氏病患者的动脉闭塞似乎是可行的。随着经验的积累,手术可安全进行,具有较高的技术和临床成功率,且无死亡率和并发症。